Boardroom Alpha
Boardroom Alpha
DVA · Current Report (Form 8-K) · Filed July 17, 2025

Davita Inc — Current Report (Form 8-K)

Form
8-K
Filed
July 17, 2025
Period
Jul 17, 2025
Ticker
DVA
Accession
0001193125-25-160501
Boardroom Alpha · Filing insights

DaVita enters Seventh Amendment to Credit Agreement, repricing Tranche B-1 and adding $250 million Tranche B-2 Term Loans.

About Davita Inc
Market cap
$12.2B
1Y TSR
+37.0%
3Y TSR
+24.5%
Board grade
B
Sector
Healthcare
CEO
Javier Rodriguez
Last annual meeting: Jun 4, 2026 · View full Davita Inc profile →
8-K
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 17, 2025

 

 

DAVITA INC.

(Exact name of registrant as specified in its charter)

 

 

 

DE   1-14106   51-0354549
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

2000 16th Street

Denver, CO 80202

(Address of principal executive offices including Zip Code)

(720) 631-2100

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:

 

Trading
symbol(s):

 

Name of each exchange
on which registered:

Common Stock, $0.001 par value   DVA   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 1.01.

Entry into a Material Definitive Agreement.

On July 17, 2025, DaVita Inc. (the “Company”) entered into a Seventh Amendment (the “Seventh Amendment”) to that certain Credit Agreement dated as of August 12, 2019 (as previously amended, restated, supplemented, or otherwise modified, and as further amended by the Seventh Amendment, the “Credit Agreement”), in each case, by and among the Company, its subsidiary guarantors, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender (“Wells Fargo”).

The Seventh Amendment, among other things, provides for (i) a repricing of the Company’s existing senior secured term loan “B” facility maturing in May 2031 (the “Extended Tranche B-1 Term Facility”; the Extended Tranche B-1 Term Facility as so repriced, the “Tranche B-2 Term Facility”, and the term “B” loans made thereunder, “Tranche B-2 Term Loans”) and (ii) an incremental borrowing of Tranche B-2 Term Loans in an aggregate principal amount of $250 million (the “Incremental Tranche B-2 Term Loans”).

Pursuant to the Seventh Amendment and the Credit Agreement, the Tranche B-2 Term Loans (including the Incremental Tranche B-2 Term Loans) shall be denominated in U.S. dollars and shall bear interest, at the Company’s option, based on (i) the Base Rate (as defined below) plus the Applicable Margin (as defined below), or (ii) the forward-looking term rate based on the secured overnight financing rate that is published by CME Group Benchmark Administration Limited (“Term SOFR”) plus the Applicable Margin. The “Base Rate” with respect to the Tranche B-2 Term Facility is defined as the highest of (i) the Federal Funds Rate, as published by the Federal Reserve Bank of New York, plus 50 basis points, (ii) the prime commercial lending rate of Wells Fargo as established from time to time and (iii) Term SOFR for an interest period of one month plus 100 basis points; provided that if the Base Rate is negative it shall be deemed to be zero. The “Applicable Margin” for the Tranche B-2 Term Facility is 175 basis points in the case of Term SOFR loans and 75 basis points in the case of Base Rate loans. The “Applicable Margin” with respect to the Extended Tranche B-1 Term Facility before giving effect to the Seventh Amendment was 200 basis points for Term SOFR loans and 100 basis points for Base Rate loans.

The Company used the proceeds of the Incremental Tranche B-2 Term Loans to repay a portion of its outstanding senior secured term “A” loans maturing in April 2028 in the amount of $250 million.

The Company and its affiliates may from time to time engage certain of the lenders under the Credit Agreement to provide other banking, investment banking and financial services.

The foregoing description of the Seventh Amendment does not purport to be complete and is qualified in its entirety by reference to the complete terms and conditions of the actual Seventh Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Seventh Amendment has been incorporated by reference herein to provide stockholders with information regarding its terms. It is not intended to provide any other information about the Company or the Company’s subsidiaries that are guarantors thereunder, or other subsidiaries and affiliates of the Company. For example, the Seventh Amendment contains representations and warranties that were made solely for the benefit of the other parties to the Seventh Amendment and should not be relied upon as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries.

 

Item 2.03.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    DAVITA INC.
Date: July 17, 2025     By:  

/s/ Joel Ackerman

      Joel Ackerman
      Chief Financial Officer and Treasurer
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Davita Inc (DVA)

Reference

Frequently asked questions

When did Davita Inc file this 8-K?
Davita Inc (DVA) filed this Current Report (Form 8-K) with the SEC on July 17, 2025. The accession number assigned by EDGAR is 0001193125-25-160501.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
DaVita enters Seventh Amendment to Credit Agreement, repricing Tranche B-1 and adding $250 million Tranche B-2 Term Loans. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Davita Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Davita Inc has filed under CIK 927066, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer